PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Clinical trials for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) trials appear
Sign up with your email to follow new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested to stop aggressive brain Cancer's return
Disease control CompletedThis study tested whether the drug nivolumab could safely prevent a type of aggressive brain lymphoma from growing back. It was for patients who had completed initial chemotherapy but still had signs of lingering cancer in their spinal fluid. The goal was to see if this maintenan…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for tough brain cancer: Three-Drug attack tested
Disease control CompletedThis study tested a combination of three drugs (ibrutinib, rituximab, and lenalidomide) for adults with lymphoma that had returned or stopped responding to treatment in the brain or spinal cord. The main goal was to find the highest safe dose of this combination. Researchers also…
Matched conditions: PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC